Bright Minds Biosciences to Present at the Stifel GMP 2nd
Link Title
Link Short URL
Link Long URL
Description:
A biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, will present virtually at the Stifel GMP 2nd Annual Future of Healthcare Conference as follows:BMB-101, a 5-HT2C selective and biased agonist, has demonstrated compelling activity in a host of in-vitro and in-vivo non-clinical tests.
Keywords (Tags):
Created by:
Bright Minds Biosciences
Created on:
Hits:
375
|